• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

St. Jude’s scientist receives ACGT grant for sarcoma gene therapy

Bioengineer by Bioengineer
February 7, 2020
in Health
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Approach will use genetically engineered immune cells to attack pediatric sarcoma

IMAGE

Credit: St. Jude Children’s Research Hospital


An innovative approach to tackling the challenges of pediatric sarcomas is being pursued by researchers at St. Jude Children’s Research Hospital (Memphis, Tennessee) with a new grant from Alliance for Cancer Gene Therapy (ACGT).

The $500,000 ACGT grant supports Stephen Gottschalk, MD, chair of Bone Marrow Transplantation and Cellular Therapy at St. Jude’s, in exploring the use of genetically engineered immune cells to attack pediatric sarcoma. Dr. Gottschalk and his team target not only the cancer, but the blood vessels supporting tumor growth. Dr. Gottschalk has conducted more than 25 previous clinical trials and most recently worked on gene therapies for treating infants with the “bubble boy” disease.

“There is an urgent need to develop meaningful treatments for children with solid tumors,” says Kevin Honeycutt, CEO and president of ACGT. “Dr. Gottschalk’s research combines state-of-the-art technologies and methodologies to attack two targeted gene proteins found in pediatric sarcomas. The members of the ACGT Scientific Advisory Council are enthusiastic about Dr. Gottschalk’s vision and very promising preliminary data.”

“Pediatric sarcoma, which comes back after initial therapy or is present at multiple sites, is difficult to treat even with the most aggressive, currently available therapies,” noted Dr. Gottschalk. “Because Sarcomas are a relatively uncommon group of cancers, accounting for about 15 percent of childhood cancers, improving outcomes has been challenging. This ACGT grant enables me to further investigate how we can leverage different proteins to attack not only abnormal sarcoma cells but also the blood vessels that provide nutrients to tumors. We’ve seen this approach work in mice. Given the resources from ACGT, we can move ahead much faster to complete all the preclinical studies that are needed to evaluate our approach in the clinic.”

Dr. Savio Woo, chairman emeritus of the ACGT Scientific Advisory Council and recently retired from the Icahn School of Medicine at Mount Sinai (New York, New York), dedicated his career to the pursuit of fundamental science and technology development in gene and cell therapy, and translating those laboratory advances into direct patient benefit. Dr. Gottschalk, who did a post-doctoral session with Dr. Woo from 1992 to 1995, acknowledges that it was Dr. Woo’s commitment to ACGT that drove his quest to secure a grant from the organization.

“Being connected to the organization that Dr. Savio Woo helped direct on the scientific side, is a great honor,” said Dr. Gottschalk.

To learn more about Alliance for Cancer Gene Therapy (ACGT), visit acgtfoundation.org, call 203-358-5055, or join the ACGT community on Facebook, Twitter, Instagram and YouTube. To learn more about St. Jude Children’s Research Hospital, visit stjude.org or follow St. Jude on social media at @stjuderesearch.

###

Alliance for Cancer Gene Therapy (ACGT)

For nearly 20 years, Alliance for Cancer Gene Therapy has funded research that is bringing innovative treatment options to people living with deadly cancers – treatments that save lives and offer new hope to all cancer patients. Founded by Barbara and Edward Netter after their daughter-in-law’s devastating death from breast cancer, ACGT funds researchers who are pioneering the potential of cancer cell and gene therapy – talented visionaries whose scientific advancements are driving the development of groundbreaking treatments for ovarian, prostate, sarcoma, glioblastoma, melanoma and pancreatic cancers. 100% of all public funds raised by ACGT directly support research. For more information, visit acgtfoundation.org, call 203-358-5055, or join the ACGT community on Facebook, Twitter, Instagram and YouTube.

Media Contact
Jenifer Howard
[email protected]
203-273-4246

Tags: cancerCell BiologyGene TherapyMedicine/HealthPediatrics
Share12Tweet8Share2ShareShareShare2

Related Posts

Innovative Care Model for Aboriginal Children in Fitzroy Valley

October 6, 2025

Texas Children’s Researchers Develop Innovative Tool to Enhance Precision in Genetic Testing

October 6, 2025

Cardiovascular Risk Factors Adversely Affect Health During and After Pregnancy

October 6, 2025

Antibodies Link COVID-19 Risk in HIV Study

October 6, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    95 shares
    Share 38 Tweet 24
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    93 shares
    Share 37 Tweet 23
  • New Insights Suggest ALS May Be an Autoimmune Disease

    71 shares
    Share 28 Tweet 18
  • Ohio State Study Reveals Protein Quality Control Breakdown as Key Factor in Cancer Immunotherapy Failure

    70 shares
    Share 28 Tweet 18

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Innovative Care Model for Aboriginal Children in Fitzroy Valley

How Black Holes Generate Intense Relativistic Jets

Texas Children’s Researchers Develop Innovative Tool to Enhance Precision in Genetic Testing

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.